The present invention provides compounds and methods for the treatment of diabeticretinopathy. In particular, LFA-I antagonists are described herein to be usedin the treatment of diabetic retinopathy. One aspect of the invention providesfor diagnosis of diabetic retinopathy and administration of a LFA-I antagonist,after the patient is diagnosed with diabetic retinopathy.